Table 2 E. coli isolated during the study from patient groups.
Weeks | 0 | 1 | 8 | 12 |
|---|---|---|---|---|
E. coli Phylogeny groups | Cipro/EcN (A) | |||
E. coli B2 | (13/25) 52% | (5/24) 21% | (10/19) 53% | (7/16) 44% |
E. coli D | (6/25) 24% | (2/24) 8% | (3/19) 16% | (1/16) 6% |
E. coli A | (5/25) 20% | (4/24) 17% | (8/19) 42% | (7/16) 44% |
E. coli B1 | (0/25) 0% | (2/24) 8% | (3/19) 16% | (3/16) 19% |
No growth | (4/25) 16% | (16/24) 67% | (0/19) 0% | (0/16) 0% |
Cipro/placebo (B) | ||||
E. coli B2 | (12/24) 50% | (1/21) 5% | (7/19) 37% | (6/15) 40% |
E. coli D | (3/24) 13% | (2/21) 10% | (3/19) 16% | (3/15) 20% |
E. coli A | (6/24) 25% | (1/21) 5% | (8/19) 42% | (3/15) 20% |
E. coli B1 | (1/24) 4% | (0/21) 0% | (3/19) 16% | (5/15) 27% |
No growth | (4/24) 17% | (17/21) 81% | (1/19) 5% | (0/15) 0% |
Placebo/EcN (C) | ||||
E. coli B2 | (8/25) 32% | (11/18) 61% | (9/14) 64% | (6/12) 50% |
E. coli D | (8 /25) 32% | (7/18) 39% | (4/14) 29% | (4/12) 33% |
E. coli A | (7/25) 28% | (2/18) 11% | (1/14) 7% | (3/12)33% |
E. coli B1 | (5/25) 20% | (2/18) 11% | (1/14) 7% | (3/12) 28% |
No growth | (2/25) 8% | (1/18) 6% | (1/14) 7% | (0/12) 0% |
Placebo/placebo (D) | ||||
E. coli B2 | (13/25) 52% | (10/24) 42% | (9/20) 45% | (6/16) 38% |
E. coli D | (5/25) 20% | (6/24) 25% | (4/20) 20% | (5/16) 31% |
E. coli A | (4/25) 16% | (8/24) 33% | (4/20) 20% | (4/16) 25% |
E. coli B1 | (6/25) 24% | (2/24) 8% | (3/20) 15% | (1/16) 6% |
No growth | (2/25) 8% | (3/24) 13% | (4/20) 20% | (1/16) 6% |
